Related Experiment Video

Updated: Feb 19, 2026

A High-Throughput Luciferase Assay to Evaluate Proteolysis of the Single-Turnover Protease PCSK9
08:14

A High-Throughput Luciferase Assay to Evaluate Proteolysis of the Single-Turnover Protease PCSK9

Published on: August 28, 2018

8.7K

PCSK9 Inhibitors: Mechanisms of Action, Metabolic Effects, and Clinical Outcomes

Connie N Hess1,2, Cecilia C Low Wang3,2, William R Hiatt1,2

  • 1Division of Cardiology and.

Annual Review of Medicine
|November 3, 2017
PubMed

Insights

New proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors offer an alternative for managing high cholesterol when statins are insufficient. These therapies target residual cardiovascular risk in patients with atherosclerotic cardiovascular disease.

Area of Science:

  • Cardiology
  • Pharmacology
  • Biochemistry

Background:

  • Atherosclerotic cardiovascular disease (ASCVD) poses a significant global health burden.
  • Elevated low-density lipoprotein cholesterol (LDL-C) is a primary risk factor for ASCVD.
  • Statins, while effective, may not adequately lower LDL-C or manage residual risk in all patients due to tolerability or efficacy limitations.

Purpose of the Study:

  • To review the development and therapeutic role of PCSK9 inhibitors in hyperlipidemia.
  • To elucidate the mechanism of action and metabolic effects of PCSK9 inhibitors.
  • To summarize clinical outcomes and cardiovascular outcome trials of PCSK9 inhibitor therapies.

Main Methods:

  • Literature review of scientific publications and clinical trial data.
  • Analysis of the mechanism of action of PCSK9 inhibition.
  • Synthesis of data on metabolic effects and clinical outcomes from relevant studies.

Main Results:

  • PCSK9 inhibitors represent a novel therapeutic class for lowering LDL-C.
  • These agents address limitations of statin therapy, including inadequate LDL-C reduction and statin intolerance.
  • Recent trials demonstrate significant cardiovascular risk reduction with PCSK9 inhibitors.

Conclusions:

  • PCSK9 inhibitors are a valuable addition to the therapeutic armamentarium for managing hyperlipidemia and reducing cardiovascular risk.
  • They offer a new strategy for patients with statin-resistant hypercholesterolemia or those experiencing adverse effects.
  • Further research and clinical application will continue to define the role of PCSK9 inhibitors in ASCVD prevention.

Keywords:
PCSK9 inhibitorcardiovascular diseasehyperlipidemia

More Related Videos

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

14.2K
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.1K

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.5K
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
25
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
465
Pharmacokinetics: Drug–Drug Interactions01:25

Pharmacokinetics: Drug–Drug Interactions

Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
499
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
573
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
208